A positive trend was also observed in users of GLP-1 RA and SGLT-2i compared with nonusers.
← all excerpts
Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes.
1
—
—